Over 35 years of biopharmaceutical experience in developing and manufacturing of biologics, vaccines and cell and gene therapies.

President of CMC Bioservices, a consultancy focused on the development and manufacturing of cell and gene therapies, biologics, and vaccines.

Greg has worked with a variety of notable companies including Novartis, Wyeth, Eli Lilly, Chiron, Centocor and Cook.  

At Novartis, he led the development of the drug substance and drug product processes for numerous monoclonal antibodies and therapeutic proteins.  In addition, Greg was a core member of Novartis’s leadership team and led the CMC efforts with respect to the acquisition of CART19 (Kymriah) from the University of Pennsylvania.  

Vice President and CSO for two years at Cook Pharmica.  

Vice President of Vaccine Development at Wyeth, where he was instrumental in the development of Prevnar, Prevnar 13 and CAIV (Cold Adapted Influenza Vaccine).

At Eli Lilly, Greg led the development and commercialization of Xigris (Activated Protein C produced in HEK293 cells) and Forteo (parathyroid hormone produced in E. coli).  

At Chiron, he developed and produced multiple recombinant vaccines produced in CHO cells, and his efforts at Centocor contributed to the development of the monoclonal antibodies Remicade, ReoPro and Centoxin.